Cardiovascular diseases remain the leading cause of mortality worldwide, with atherosclerosis, a chronic inflammatory disorder of the arterial wall, at the core of heart attacks and strokes (1) .  Recent advances in immunology and protein engineering have opened new avenues for combating cardiovascular disease, notably, the development of vaccines targeting endogenous proteins involved in cholesterol metabolism. While conventional treatments like statins and monoclonal antibodies (mAbs) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have made significant strides in lowering low-density lipoprotein cholesterol (LDL-C), limitations in efficacy, cost, and compliance necessitate innovative approaches. A recent article (Pre-proof) published in the journal Molecular Therapy: Methods & Clinical Development by researchers at the National Institute of Chemistry (Kemijski inštitut, Ljubljana) and the University of Ljubljana introduces a novel paradigm: a chimeric PCSK9-based vaccine that elicits long-lasting antibody responses without triggering cytotoxic T-cell–mediated autoimmunity (2).

Atherosclerosis- A Silent Killer

Atherosclerosis, the insidious buildup of fatty plaques within arterial walls, remains the world’s leading cause of death (1). This chronic inflammatory condition narrows arteries over decades, culminating in heart attacks or strokes when plaques rupture. Hypercholesterolemia, particularly elevated LDL-C, is a major risk factor. LDL particles infiltrate the vascular endothelium, triggering immune cell infiltration and oxidative stress, leading to plaque formation and vascular remodeling (3). Persistent exposure to elevated LDL-C exacerbates the disease over decades, eventually leading to vascular occlusion. While statins revolutionized treatment by inhibiting cholesterol synthesis, a significant portion of high-risk patients fail to achieve target LDL-cholesterol (LDL-C) levels.

Atherosclerosis typically begins in childhood with the development of fatty streaks and progresses silently for decades without symptoms. This progression is driven by major risk factors, including high cholesterol (LDL), high blood pressure, smoking, diabetes, obesity, and physical inactivity. If left unchecked, the disease leads to serious complications such as coronary artery disease (blockages in heart arteries), peripheral artery disease (reduced blood flow to limbs), stroke (blocked blood flow to the brain), and heart attack (damage from blocked heart arteries).

PCSK9: The Cholesterol Gatekeeper

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that regulates cholesterol homeostasis by promoting the degradation of low-density lipoprotein receptors (LDLR) on liver cells (4). Fewer LDLRs mean less cholesterol is cleared from the blood, resulting in higher LDL cholesterol (LDL-C) levels, a major risk factor for atherosclerosis and heart attack.

Targeting PCSK9 is supported by strong genetic and clinical evidence. Gain-of-function mutations in the PCSK9 gene are known to cause familial hypercholesterolemia by enhancing degradation of LDL receptors, thereby raising LDL cholesterol (LDL-C) levels (5). Conversely, individuals with loss-of-function mutations in PCSK9 exhibit significantly lower LDL-C levels and a reduced risk of cardiovascular disease (6). Clinically, monoclonal antibody-based PCSK9 inhibitors such as evolocumab and alirocumab have been shown to reduce LDL-C by up to 60%, resulting in a marked decrease in cardiovascular events (7). Importantly, the role of PCSK9 extends beyond cholesterol metabolism, it has also been implicated in promoting platelet activation and vascular inflammation, further reinforcing its connection to atherosclerosis and the risk of heart attack.

This established PCSK9 as a prime therapeutic target in the fight against hypercholesterolemia and cardiovascular disease. Several therapeutic approaches have been developed. Monoclonal antibodies (mAbs), such as evolocumab and alirocumab, are highly effective in reducing LDL-C levels by 50–60% (7). However, they require frequent administration—typically every 2 to 4 weeks—and are associated with high treatment costs. Small interfering RNA (siRNA) therapies, like inclisiran, offer the advantage of longer-lasting LDL-C reduction, with effects that can persist for approximately six months following a single dose (8).

Early efforts to develop PCSK9 vaccines focused on peptide-based formulations, using short amino acid sequences to elicit antibody responses (9). These vaccines demonstrated moderate reductions in LDL-C levels in animal models and early clinical investigations. Building on this foundation, virus-like particle (VLP)–based PCSK9 vaccines were introduced to enhance immunogenicity. By displaying PCSK9 epitopes on VLP scaffolds, these vaccines achieved stronger and more durable antibody responses, leading to improved LDL-C lowering in preclinical studies. Several of these VLP-based vaccine candidates have advanced into nonhuman primate trials, showing promise for future clinical development.

More recently, gene editing approaches have emerged as a potentially permanent solution to suppress PCSK9 expression (10). While promising, these strategies currently face significant challenges related to safety, off-target effects, and efficient delivery systems.

Chimeric Vaccines: A Hybrid Approach to Broad-Spectrum Immunity

A chimeric vaccine is a recombinant immunization approach that integrates genetic or structural components from two or more distinct pathogens into a single formulation (11). By combining antigenic regions, such as surface proteins or specific epitopes, from different microorganisms, these vaccines are designed to elicit broad or cross-protective immune responses that can target multiple strains or species. The strategy focuses on preserving critical antigenic determinants to ensure strong activation of both antibody and T-cell responses, while enhancing safety by removing virulence factors that could cause disease. In practical applications, this can involve techniques such as exchanging structural genes, like the pre-membrane and envelope proteins among related flaviviruses, or engineering fusion proteins that display epitopes from various pathogens on a unified molecular scaffold. This design enables chimeric vaccines to provide effective, targeted immunity across a wide range of infectious threats.

Chimeric PCSK9 Vaccine: Engineering a Breakthrough

One of the major challenges in developing vaccines against self-proteins like PCSK9 is overcoming immune tolerance while avoiding autoimmune responses. Endogenous proteins typically make poor immunogens due to central and peripheral tolerance mechanisms that eliminate or silence autoreactive T and B cells. To address this, researchers engineered a chimeric PCSK9 (chPCSK9) vaccine that strategically preserves key conformational B-cell epitopes from human PCSK9 to elicit an effective antibody response. At the same time, they eliminated cytotoxic T lymphocyte (CTL) epitopes by replacing internal sequences with homologous regions from PCSK9 derived from the distantly related Ocean sunfish (Mola mola), thereby minimizing the risk of T-cell–mediated autoimmunity.

This rational design yielded a vaccine that induced strong humoral immunity, evidenced by high-titer PCSK9-specific IgG antibodies, without provoking proinflammatory T-cell responses such as interferon-gamma (IFNγ) or interleukin-2 (IL-2) secretion. Notably, the antibody response   was sustained up to 24 weeks, with some decline for hPCSK9 around week 18. In vivo studies using the Apoe⁻/⁻ mouse model of atherosclerosis further validated the vaccine’s efficacy. Immunized mice exhibited marked reductions in serum PCSK9, LDL-C, and triglyceride levels, alongside increased hepatic LDL receptor (LDLR) expression. Moreover, vaccination led to decreased inflammatory gene expression in liver tissue and reduced lipid plaque accumulation and monocyte infiltration in the aortic arch. These results not only confirmed the vaccine’s biochemical efficacy but also demonstrated significant histological and physiological improvements over the 24-week study period.

Conclusion

The chimeric PCSK9 vaccine represents a promising step toward long-lasting, cost-effective therapies for atherosclerosis and heart attack prevention. By merging immunology, structural biology, and rational protein design, this study redefines the boundaries of vaccinology, offering a glimpse into a future where we may vaccinate not only against viruses but also against our own disease-driving proteins.

References

  1. Atherosclerosis.Nat Rev Dis Primers 2019;  5: 56. https://doi.org/10.1038/s41572-019-0106-z
  2. Engineering chimeric PCSK9 for a vaccine against atherosclerosis. Molecular Therapy: Methods & Clinical Development. 2025. S2329-0501(25)00130-5. https://doi.org/10.1016/j.omtm.2025.101535
  3. Hypercholesterolemia Induces Vascular Cell Dysfunction: Molecular Basis for Atherosclerosis. Austin J Vasc Med. 2015; 2: 1011.https://austinpublishinggroup.com/vascular-medicine/fulltext/ajvm-v2-id1011.php
  4. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol; 2014; 25:387–393. doi: 1097/MOL.0000000000000114 https://pmc.ncbi.nlm.nih.gov/articles/PMC4166010/
  5. PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia. Anatol J Cardiol. 2017;18266–272. doi: 14744/AnatolJCardiol.2017.7654
  6. PCSK9Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data from Nine Studies of African Americans and Whites. Circ Cardiovasc Genet. 2017; 10:e001632. doi:1161/CIRCGENETICS.116.001632
  7. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Rev Cardiovasc Med. 2024 May 23;25(5):190. doi: 31083/j.rcm2505190\
  8. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020;382:1507-1519 DOI: 10.1056/NEJMoa1912387
  9. Peptide-Based Anti-PCSK9 Vaccines – An Approach for Long-Term LDLc Management.  PLoS ONE 9(12): e114469. https://doi.org/10.1371/journal.pone.0114469.
  10. A potent epigenetic editor targeting human PCSK9for durable reduction of low-density lipoprotein cholesterol levels. Nat Med 31, 1329–1338 (2025). https://doi.org/10.1038/s41591-025-03508-x
  11. Challenges and Opportunities in the Process Development of Chimeric Vaccines. Vaccines 2023, 11(12), 1828; https://doi.org/10.3390/vaccines11121828

 

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)